HomeCompareCBLI vs MRK

CBLI vs MRK: Dividend Comparison 2026

CBLI yields 63.09% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CBLI wins by $700.5K in total portfolio value
10 years
CBLI
CBLI
● Live price
63.09%
Share price
$3.17
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$757.3K
Annual income
$183,899.77
Full CBLI calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — CBLI vs MRK

📍 CBLI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCBLIMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CBLI + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CBLI pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CBLI
Annual income on $10K today (after 15% tax)
$5,362.78/yr
After 10yr DRIP, annual income (after tax)
$156,314.80/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, CBLI beats the other by $147,986.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CBLI + MRK for your $10,000?

CBLI: 50%MRK: 50%
100% MRK50/50100% CBLI
Portfolio after 10yr
$407.0K
Annual income
$96,848.95/yr
Blended yield
23.79%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

CBLI
Analyst Ratings
3
Buy
1
Hold
Consensus: Buy
Altman Z
435.1
Piotroski
1/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CBLI buys
0
MRK buys
0
No recent congressional trades found for CBLI or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCBLIMRK
Forward yield63.09%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$757.3K$56.8K
Annual income after 10y$183,899.77$9,798.13
Total dividends collected$633.8K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: CBLI vs MRK ($10,000, DRIP)

YearCBLI PortfolioCBLI Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$17,009$6,309.15$11,206$366.19+$5.8KCBLI
2$28,229$10,029.27$12,650$502.35+$15.6KCBLI
3$45,761$15,556.06$14,407$694.19+$31.4KCBLI
4$72,532$23,567.66$16,585$967.82+$55.9KCBLI
5$112,521$34,911.29$19,342$1,363.89+$93.2KCBLI
6$171,013$50,615.56$22,913$1,947.19+$148.1KCBLI
7$254,878$71,894.60$27,662$2,823.89+$227.2KCBLI
8$372,862$100,142.13$34,159$4,173.35+$338.7KCBLI
9$535,876$136,914.14$43,337$6,308.80+$492.5KCBLI
10$757,287$183,899.77$56,776$9,798.13+$700.5KCBLI

CBLI vs MRK: Complete Analysis 2026

CBLIStock

Cleveland BioLabs, Inc. operates as a biopharmaceutical company, which engages in the research and development of drugs. The company is headquartered in Buffalo, New York and currently employs 15 full-time employees. The firm is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.

Full CBLI Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this CBLI vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CBLI vs SCHDCBLI vs JEPICBLI vs OCBLI vs KOCBLI vs MAINCBLI vs JNJCBLI vs ABBVCBLI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.